• Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis 

      Weismüller T.J., Strassburg C.P., Trivedi P.J., Hirschfield G.M., Trivedi P.J., Bergquist A., Said K., Imam M., Lazaridis K.N., Juran B.D., Cheung A., Lindor K.D., Weismüller T.J., Lenzen H., Manns M.P., Ponsioen C.Y., Beuers U., Holm K., Naess S., Karlsen T.H., Schrumpf E., Boberg K.M., Gotthardt D., Rupp C., Färkkilä M.A., Jokelainen K., Marschall H.-U., Benito de Valle M., Thorburn D., Saffioti F., Weersma R.K., Fevery J., Mueller T., Chazouillères O., Schulze K., Schramm C., Almer S., Pereira S.P., Levy C., Mason A., Bowlus C.L., Floreani A., Halilbasic E., Trauner M., Yimam K.K., Milkiewicz P., Milkiewicz P., Huynh D.K., Pares A., Manser C.N., Dalekos G.N., Eksteen B., Invernizzi P., Berg C.P., Kirchner G.I., Sarrazin C., Zimmer V., Fabris L., Braun F., Marzioni M., Schramm C., Chapman R.W., Chapman R.W., Lindor K.D., Imam M., Lindor K.D., Naess S., Karlsen T.H., Schrumpf E., Boberg K.M., Hansen B.E., Hansen B.E., Hansen B.E., on behalf of the, International PSC Study Group (2017)
      Background & Aims Primary sclerosing cholangitis (PSC) is an orphan hepatobiliary disorder associated with inflammatory bowel disease (IBD). We aimed to estimate the risk of disease progression based on distinct clinical ...
    • The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B 

      Papatheodoridis G.V., Idilman R., Dalekos G.N., Buti M., Chi H., van Boemmel F., Calleja J.L., Sypsa V., Goulis J., Manolakopoulos S., Loglio A., Siakavellas S., Keskın O., Gatselis N., Hansen B.E., Lehretz M., de la Revilla J., Savvidou S., Kourikou A., Vlachogiannakos I., Galanis K., Yurdaydin C., Berg T., Colombo M., Esteban R., Janssen H.L.A., Lampertico P. (2017)
      Whether there is a change of hepatocellular carcinoma (HCC) incidence in chronic hepatitis B patients under long-term therapy with potent nucleos(t)ide analogues is currently unclear. We therefore assessed the HCC incidence ...
    • Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B 

      Papatheodoridis G.V., Dalekos G.N., Idilman R., Sypsa V., Van Boemmel F., Buti M., Calleja J.L., Goulis J., Manolakopoulos S., Loglio A., Papatheodoridi M., Gatselis N., Veelken R., Lopez-Gomez M., Hansen B.E., Savvidou S., Kourikou A., Vlachogiannakos J., Galanis K., Yurdaydin C., Esteban R., Janssen H.L.A., Berg T., Lampertico P. (2020)
      Background & Aims: A recent study in Asian patients with chronic hepatitis B (CHB) reported that the incidence of hepatocellular carcinoma (HCC) was lower in patients treated with tenofovir disoproxil fumarate (TDF) than ...